EBIT at other companies
Other financials
Where this comes from
Calculated from Taysha Gene Therapies, Inc.’s reported figures.
The official record: Taysha Gene Therapies, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Taysha Gene Therapies, Inc.'s ebit.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Taysha Gene Therapies, Inc.'s EBIT?
- Taysha Gene Therapies, Inc. (TSHA) reported EBIT of -$43.49M in Q1 2026.
- How has Taysha Gene Therapies, Inc.'s EBIT changed year-over-year?
- Taysha Gene Therapies, Inc.'s EBIT decreased by 103.0% year-over-year, from -$21.42M to -$43.49M.
- What is the long-term trend for Taysha Gene Therapies, Inc.'s EBIT?
- Over 4 years (2021 to 2025), Taysha Gene Therapies, Inc.'s EBIT has grown at a -10.6% compound annual growth rate (CAGR), from -$173.27M to -$110.5M.
- What does EBIT mean?
- Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.